DOCSLIB.ORG

Biological Effect of Calcium and Vitamin D Dietary Supplements Against Osteoporosis in Ovariectomized Rats Reham A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Biological Effect of Calcium and Vitamin D Dietary Supplements Against Osteoporosis in Ovariectomized Rats Reham A Progress in Nutrition 2018; Vol. 20, N. 1: 86-93 DOI: 10.23751/pn.v20i1.5223 © Mattioli 1885 Original article Biological effect of calcium and vitamin D dietary supplements against osteoporosis in ovariectomized rats Reham A. Mustafa1, Nehal A. A. Alfky1, Haifa H. Hijazi1, Eslam A. Header1,2, Firas S. Azzeh1 1 Clinical Nutrition Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, KSA. - E-mail: [email protected]; 2Department of Nutrition and Food Science Faculty of Home Economics Minufiya University, Egypt. Summary. There is a direct association between the lack of estrogen and the progress of osteoporosis. This study was done to evaluate the biological effect of diet supplementation with calcium (Ca), and vitamin D (VD) on osteoporosis in ovariectomized (OVX) rats and to examine the possible potential mechanisms. Twenty-eight rats were randomly divided into 4 equal groups (n=7). To induce estrogen deficiency in rats, bilateral ovariectomy and sham (SHAM; negative control) surgery were done. In the basal diet, Ca and VD was supplemented with 210 mg/kg and 600 IU/kg, respectively, for 6 weeks. Alendronate as a standard anti- osteoporotic drug was used in a single weekly dose (3 mg/kg) for 6 weeks. After six weeks, serum markers of osteoporosis and bone femur status were evaluated. The results exposed that Ca and VD supplementation increased the body weight gain and diminished the uterine weight as a result of ovariectomy operation. These supplements significantly raised the serum Ca, bone-specific alkaline phosphatase, free thyroxin, and osteo- calcin in OVX-rats, while the serum interleukin-1beta, interleukin-6, parathormone, and pyridinoline levels were significantly dropped. There were also significantly improved in femur bone mineral density and bone ash contents, mainly Ca and phosphorous. In conclusion, feeding of Ca and VD dietary supplements have an anti-osteoporotic activity in OVX rats due to improvement of bone formation and abolition of bone loss. The study recommends that intake of Ca and VD together may be beneficial for the inhibition of osteoporosis in postmenopausal women due to estrogen deficiency. Key words: calcium, vitamin D, osteoporosis, bone mineral density Introduction elderly women and younger postmenopausal women. Moreover, menopause drastically increases the risk of Osteoporosis is a silently progressing disease of osteoporosis (3). Postmenopausal osteoporosis occurs bones characterized by low bone mass and decreased due to imbalance between osteoblastic bone formation bone mineral density (BMD) leading to high inci- and osteoclastic bone resorption as a result of estrogen dence of bone fragility and fractures (1). The mass of loss (4). Estrogen deficiency is the most potent initiator skeletal bone is controlled by a combination of some of osteoclastic bone loss and has been associated with endogenous (genes, metabolic hormones) and exoge- osteoporosis (5). In addition to maintaining adequate nous (nutrition, exercise) factors (2). Osteoporosis rep- Ca and VD intake and practicing exercise, the preven- resents a serious health problem that prevails among tive measures against osteoporosis include avoiding Biological effect of calcium and vitamin D dietary supplements against osteoporosis in ovariectomized rats 87 of smoking, excessive alcohol and caffeine intake (6). obtained in the form of tablets each contains 70 mg Estrogen, Ca, VD, calcitonin and several antioxidants Alendronate sodium. The dose of Alendronate 3 mg/ help in the prevention of postmenopausal osteoporosis kg body weight (b.wt)/week was orally given to rats (7, 8). Estrogen replacement therapy (ERT) has been according to Maria et al. (17). established as a regimen for prevention of postmeno- pausal bone loss, but long term ERT may be accom- Rats panied with severe adverse effects and increased risk of Twenty-eight mature female Sprague Dawley rats ovarian and endometrial cancers (9, 10). (235-245 g b.wt and 10-12 weeks old) were used in Nutrition plays an important role in bone health, this study. The rats were purchased from Laboratory and there is an increasing interest in dietary nutrients Animal Colony, Helwan, Egypt. The animals were which influence bone metabolism and health such as housed under hygienic conditions at room temperature Ca and VD. Reduced dietary intake of Ca is associ- of 24°C, relative humidity of 50% and 12 hr light/12 ated with reduced bone mass and leads to osteoporosis. hr dark cycles. The rats were fed on either basal or ex- Chronic VD deficiency leads to osteomalacia (11). On perimental diets and water was provided as required. the other side, adequate intake of Ca and VD is essen- The experiment on rats was carried out according to tial for bone health (2, 7, 11). the National regulations on animal welfare and Insti- Oxidative stress, resulting from excessive forma- tutional Animal Ethical Committee. tion of reactive oxygen species (ROS) or lowering of body antioxidant defense system, represents a main Basal and experimental diets cause of postmenopausal bone loss (12). ROS are in- The dietary supply of protein, fat, carbohydrates, volved in bone resorption because of superoxide free vitamins and minerals was equivalent to the recom- radicals generate osteoclastic bone loss (13). Oxidative mended dietary allowances for rats according to stress increased differentiation and function of osteo- Reeves et al. (18). Basal diet consisted of 20% protein, clasts, so increasing bone loss (14). 10% sucrose, 5% corn oil, 2% choline chloride, 1% vi- Therefore, the present study was undertaken to tamin mixture, 3.5% salt mixture and 5% fibers. The evaluate the effect of Ca and VD micronutrients on remainder was corn starch up to 100%. Experimental serum and bone biomarkers of osteoporosis in ovari- diets were basal diet supplemented with Ca (210 mg/ ectomized rat model, and to examine the potential kg) and VD (600 IU/kg). mechanisms. Ovariectomy procedure Under ether anesthesia, the bilateral ovariectomy Materials and methods was performed in rats by making two dorsolateral in- cisions using sharp dissecting scissors. The skin and Dietary supplements dorsal muscles were then cut and the peritoneal cav- Calcium carbonate was procured from El- ity was thus reached. The uterine horn was picked out Gomhoryia Company, Egypt, in the form of fine and the fatty tissue around the ovary was removed. powder. Calcium carbonate is widely used as an The connection between the Fallopian tube and the inexpensive dietary Ca supplement. It was added uterine horn was clamped by artery forceps and cut to basal diet at 210 mg/kg according to Chen et al. was made under the clamped area to remove the ovary. (15). Vitamin D (Cholecalciferol, vitamin D3) was Skin was closed bilaterally with one simple catgut su- obtained in the form of capsules and added to basal ture. Tincture iodine solution (antiseptic) was applied diet at 600 IU/kg according to Ghanizadeh et al. (16). locally on the skin at both sites of the operation. This technique was described by Lasota and Danowska- Alendronate drug Klonowska (19). Similarly, sham (SHAM) operation Alendronate (Fosamax®, Merck Sharp and was performed where the ovaries were exposed but not Dohme Company, USA) is class of bisphosphonates removed. that widely used for treatment of osteoporosis. It was 88 R. A. Mustafa, N.A. A. Alfky, H. H. Hijazi, et al. Experimental design using Vernier caliper. Femur bone volume and BMD Twenty-eight rats were randomized into to 4 were calculated according to the principle of Archi- equal groups. Group 1 was sham-operated (SHAM) medes (25). In brief, the femur was cut out at the mid and fed on basal diet and the other 3 groups were diaphyses and bone marrow washed out. Each femur ovariectomized (OVX) and left for 3 weeks post-op- bone was placed in a vial filled with deionized wa- eration to ensure almost complete clearance of their ter and the vial was placed in vacuum desiccator for bodies from sex hormone residues. Group 2 was kept 90 minutes. The femurs were removed from the vial, OVX (positive control) and fed on basal diet. Group 3 dried by blotted paper, weighed, and placed again in was fed on experimental diets supplemented with Ca other vial containing deionized water. The bone was + VD for 6 weeks. Group 4 was orally given Alen- reweighed and bone volume was measured. Femur dronate (standard anti-osteoporotic drug) in a single BMD was calculated using this formula: BMD = fe- weekly dose (3 mg/kg) for 6 weeks. The initial and fi- mur weight/femur volume. To obtain the ash, femur nal body weights of rats were recorded and changes bones were dehydrated and defatted in acetone and in weight gains were calculated. Blood samples were anhydrous ether, dried for 6 hr in an oven at 700°C. collected for biochemical analyses. The rats were then The remaining ash was weighed, solubilized with 0.1 euthanized by prolonged exposure to ether anesthetic Mol/L HCl, transferred into volumetric flask and and uterine horns were dissected out and weighed. Fe- completed to 100 ml with 0.1Mol/L HCl according mur bones were dissected out and prepared for bone to Yang et al. (26). The final solution was used for es- analysis. timation of calcium and phosphorus in the ash using colorimetric methods. Biochemical analyses Blood samples were withdrawn by cardiac punc- Statistical analysis ture, left standing for 10 minutes to clot and centri- Data were presented as means ± standard error fuged at 12000 rpm for 15 minutes to separate the (SE). The statistical analysis was performed using com- serum which kept frozen at – 80°C till biochemical puterized statistical package of social sciences (SPSS, analyses. Serum concentrations of Ca (20) and phos- version 20) program with one-way analysis of variance phorus (21) were colorimetrically determined using (ANOVA) followed by Duncan›s multiple range tests specific diagnostic reagent kits (BioMérieux, France) according to Snedecor and Cochran (27).
Load more

Recommended publications
  • Daily Lifestyle Modifications to Improve Quality of Life And
    brain sciences Review Daily Lifestyle Modifications to Improve Quality of Life and Survival in Glioblastoma: A Review Sarah Travers and N. Scott Litofsky * Division of Neurosurgery, University of Missouri School of Medicine, Columbia, MO 65212, USA; [email protected] * Correspondence: [email protected] Abstract: Survival in glioblastoma remains poor despite advancements in standard-of-care treatment. Some patients wish to take a more active role in their cancer treatment by adopting daily lifestyle changes to improve their quality of life or overall survival. We review the available literature through PubMed and Google Scholar to identify laboratory animal studies, human studies, and ongoing clinical trials. We discuss which health habits patients adopt and which have the most promise in glioblastoma. While results of clinical trials available on these topics are limited, dietary restrictions, exercise, use of supplements and cannabis, and smoking cessation all show some benefit in the comprehensive treatment of glioblastoma. Marital status also has an impact on survival. Further clinical trials combining standard treatments with lifestyle modifications are necessary to quantify their survival advantages. Keywords: survival in glioblastoma; dietary restriction in glioblastoma; cannabis use in glioblastoma; supplementation in glioblastoma; glioblastoma health modifications Citation: Travers, S.; Litofsky, N.S. Daily Lifestyle Modifications to 1. Introduction Improve Quality of Life and Survival Glioblastoma remains the most aggressive and deadly form of primary brain tumor, in Glioblastoma: A Review. Brain Sci. with average survival rates ranging from 7.8 to 23.4 months after diagnosis [1]. Maximal 2021, 11, 533. https://doi.org/ surgical resection followed by radiation and temozolomide have become standard of 10.3390/brainsci11050533 care [2,3].
    [Show full text]
  • Acne Vulgaris and Intake of Selected Dietary Nutrients—A Summary of Information
    healthcare Review Acne Vulgaris and Intake of Selected Dietary Nutrients—A Summary of Information Aleksandra Podgórska †, Anna Pu´scion-Jakubik*,† , Renata Markiewicz-Zukowska˙ , Krystyna Joanna Gromkowska-K˛epkaand Katarzyna Socha Department of Bromatology, Faculty of Pharmacy with the Division of Laboratory Medicine, Medical University of Białystok, Mickiewicza 2D Street, 15-222 Białystok, Poland; [email protected] (A.P.); [email protected] (R.M.-Z.);˙ [email protected] (K.J.G.-K.); [email protected] (K.S.) * Correspondence: [email protected]; Tel.: +48-8574-854-69 † Contributed equally. Abstract: Acne vulgaris (AV) is a chronic disease that affects a significant percentage of the world’s population. Its development is influenced by both external and internal factors. The purpose of this review is to demonstrate the effect of basic nutrient intake on the exacerbation or alleviation of AV lesions. A retrospective review of publications in PubMed regarding diet therapy and the impact of individual nutrient intake on the skin condition of patients was conducted. Ingestion of products with a high glycaemic index may indirectly lead to sebum overproduction, which promotes infection with Cutibacterium acnes and causes inflammation. Consumption of certain dairy products may result Citation: Podgórska, A.; in skin deterioration caused by the presence of hormones in these products, i.e., progesterone and Pu´scion-Jakubik,A.; testosterone precursors. The beneficial effect of fatty acids on the skin is manifested by the reduction Markiewicz-Zukowska,˙ R.; Gromkowska-K˛epka,K.J.; Socha, K. in inflammation. Of significance in AV treatment are vitamins A, C, D, E and B, as well as mineral Acne Vulgaris and Intake of Selected elements zinc and selenium.
    [Show full text]
  • Animal Models of Osteoporosis - Necessity and Limitations
    A.European Simon TurnerCells and Materials V ol. 1. 2001 (pages 66-81) DOI: 10.22203/eCM.v001a08 Running title: Animal models ISSN - osteoporosis 1473-2262 ANIMAL MODELS OF OSTEOPOROSIS - NECESSITY AND LIMITATIONS A. Simon Turner* Department of Clinical Sciences, Colorado State University, Ft. Collins, CO 80523, USA. Abstract Review of Animal Models of Osteoporosis There is a great need to further characterise the available General introduction to the need for animal models animal models for postmenopausal osteoporosis, for the Postmenopausal osteoporosis is a major health prob- understanding of the pathogenesis of the disease, investi- lem for women, the understanding of which is hindered by gation of new therapies (e.g. selective estrogen receptor the difficulty of studying a disease that is restricted to modulators (SERMs)) and evaluation of prosthetic devices humans. Osteoporosis is a slowly progressive disease, in osteoporotic bone. Animal models that have been used necessitating a study of several years’ duration to allow in the past include non-human primates, dogs, cats, ro- for a response to therapy. Because results come slowly, dents, rabbits, guinea pigs and minipigs, all of which have accumulation of data is time consuming, and maintenance advantages and disadvantages. Sheep are a promising of a study group is made more difficult by natural attrition model for various reasons: they are docile, easy to handle due to either relocation or death. and house, relatively inexpensive, available in large num- Lifestyle and health-related factors such as smoking, bers, spontaneously ovulate, and the sheep’s bones are alcoholism, and diet have been linked with an increased large enough to evaluate orthopaedic implants.
    [Show full text]
  • Vitamin D and Its Analogues Decrease Amyloid- (A) Formation
    International Journal of Molecular Sciences Article Vitamin D and Its Analogues Decrease Amyloid-β (Aβ) Formation and Increase Aβ-Degradation Marcus O. W. Grimm 1,2,3,*,† ID , Andrea Thiel 1,† ID , Anna A. Lauer 1 ID , Jakob Winkler 1, Johannes Lehmann 1,4, Liesa Regner 1, Christopher Nelke 1, Daniel Janitschke 1,Céline Benoist 1, Olga Streidenberger 1, Hannah Stötzel 1, Kristina Endres 5, Christian Herr 6 ID , Christoph Beisswenger 6, Heike S. Grimm 1 ID , Robert Bals 6, Frank Lammert 4 and Tobias Hartmann 1,2,3 1 Experimental Neurology, Saarland University, Kirrberger Str. 1, 66421 Homburg/Saar, Germany; [email protected] (A.T.); [email protected] (A.A.L.); [email protected] (J.W.); [email protected] (J.L.); [email protected] (L.R.); [email protected] (C.N.); [email protected] (D.J.); [email protected] (C.B.); [email protected] (O.S.); [email protected] (H.S.); [email protected] (H.S.G.); [email protected] (T.H.) 2 Neurodegeneration and Neurobiology, Saarland University, Kirrberger Str. 1, 66421 Homburg/Saar, Germany 3 Deutsches Institut für DemenzPrävention (DIDP), Saarland University, Kirrberger Str. 1, 66421 Homburg/Saar, Germany 4 Department of Internal Medicine II–Gastroenterology, Saarland University Hospital, Saarland University, Kirrberger Str. 100, 66421 Homburg/Saar, Germany; [email protected] 5 Department of Psychiatry and Psychotherapy, Clinical Research Group, University Medical Centre Johannes Gutenberg, University of Mainz, Untere Zahlbacher Str. 8, 55131 Mainz, Germany; [email protected] 6 Department of Internal Medicine V–Pulmonology, Allergology, Respiratory Intensive Care Medicine, Saarland University Hospital, Kirrberger Str.
    [Show full text]
  • Preserved Bone Mass in Ovariectomized Rats Treated With
    Preserved bone mass in ovariectomized rats treated with parathyroid-hormone-related peptide (1-34) and (107-111) fragments J Rouffet, Veronique Coxam, N Gaumet, Jp Barlet To cite this version: J Rouffet, Veronique Coxam, N Gaumet, Jp Barlet. Preserved bone mass in ovariectomized rats treated with parathyroid-hormone-related peptide (1-34) and (107-111) fragments. Reproduction Nutrition Development, EDP Sciences, 1994, 34 (5), pp.473-481. hal-00899674 HAL Id: hal-00899674 https://hal.archives-ouvertes.fr/hal-00899674 Submitted on 1 Jan 1994 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Original article Preserved bone mass in ovariectomized rats treated with parathyroid-hormone-related peptide (1-34) and (107-111) fragments J Rouffet V Coxam N Gaumet JP Barlet1 1 INRA-Theix, Métabolisme Minéral, 63122 Saint-Genès-Champanelle, France; 2 Radiobiology Division, School of Medicine, University of Utah, Salt Lake City, UT 84112, USA (Received 28 April 1994; accepted 25 July 1994) Summary ― The effect of synthetic human PTHrP (1 -34) or (107-111) fragments on bone loss was stud- ied in rats, one month after ovariectomy (OVX). Four groups of 7-8-month-old rats were treated sc daily for 13 d with PTHrP (1-34) or (107-111 ) at the dose of 1 or 3 nmol/100 g body weight.
    [Show full text]
  • Toiminta Unita on Ulla La Mungukurti |
    TOIMINTAUNITA USON 20180071390A1ULLA LA MUNGUKURTI | ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2018/ 0071390 A1 PATEL et al. (43 ) Pub . Date : Mar . 15 , 2018 ( 54 ) COMPOSITIONS OF PHARMACEUTICAL A61K 9 / 06 (2006 .01 ) ACTIVES CONTAINING DIETHYLENE A61K 9 /00 (2006 .01 ) GLYCOL MONOETHYL ETHER OR OTHER A61K 31 /573 ( 2006 .01 ) ALKYL DERIVATIVES A61K 31/ 565 ( 2006 .01 ) A61K 31/ 4439 ( 2006 . 01 ) ( 71 ) Applicant : THEMIS MEDICARE LIMITED , A61K 31 / 167 ( 2006 . 01 ) Mumbai (IN ) A61K 31 / 57 (2006 . 01) (52 ) U . S . CI. (72 ) Inventors : Dinesh Shantilal PATEL , Mumbai CPC .. .. .. A61K 47 / 10 ( 2013 . 01 ) ; A61K 9 /4858 ( IN ) ; Sachin Dinesh PATEL , Mumbai ( 2013 .01 ) ; A61K 9 /08 ( 2013 .01 ) ; A61K 9 / 06 ( IN ) ; Shashikant Prabhudas ( 2013 .01 ) ; A61K 9 / 0014 ( 2013 .01 ) ; A61K KURANI, Mumbai ( IN ) ; Madhavlal 31/ 573 ( 2013 .01 ) ; A61K 31 /57 ( 2013 .01 ) ; Govindlal PATEL , Mumbai ( IN ) A61K 31/ 565 ( 2013 .01 ) ; A61K 31 /4439 (73 ) Assignee : THEMIS MEDICARE LIMITED , ( 2013 .01 ) ; A61K 31/ 167 ( 2013 .01 ) ; A61K Mumbai (IN ) 9 /0048 ( 2013 .01 ) ; A61K 9 /0019 (2013 .01 ) ( 57 ) ABSTRACT (21 ) Appl. No .: 15 / 801, 390 The present invention relates to pharmaceutical composi tions of various pharmaceutical actives, especially lyophilic ( 22 ) Filed : Nov . 2 , 2017 and hydrophilic actives containing Diethylene glycol mono ethyl ether or other alkyl derivatives thereof as a primary Related U . S . Application Data vehicle and /or to pharmaceutical compositions utilizing (62 ) Division of application No. 14 /242 , 973 , filed on Apr. Diethylene glycol monoethyl ether or other alkyl derivatives 2 , 2014 , now Pat. No. 9 , 827 ,315 .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL Et Al
    US 20140296.191A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL et al. (43) Pub. Date: Oct. 2, 2014 (54) COMPOSITIONS OF PHARMACEUTICAL (52) U.S. Cl. ACTIVES CONTAINING DETHYLENE CPC ............... A61K 47/10 (2013.01); A61 K9/0019 GLYCOL MONOETHYLETHER OR OTHER (2013.01); A61 K9/0048 (2013.01); A61 K ALKYL DERVATIVES 45/06 (2013.01) USPC ........... 514/167: 514/177; 514/178: 514/450; (71) Applicant: THEMIS MEDICARE LIMITED, 514/334: 514/226.5: 514/449; 514/338; Mumbai (IN) 514/256; 514/570; 514/179; 514/174: 514/533; (72) Inventors: Dinesh Shantilal PATEL, Mumbai (IN); 514/629; 514/619 Sachin Dinesh PATEL, Mumbai (IN); Shashikant Prabhudas KURANI, Mumbai (IN); Madhavlal Govindlal (57) ABSTRACT PATEL, Mumbai (IN) (73) Assignee: THEMIS MEDICARE LIMITED, The present invention relates to pharmaceutical compositions Mumbai (IN) of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl (21) Appl. No.: 14/242,973 ether or other alkyl derivatives thereofas a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene (22) Filed: Apr. 2, 2014 glycol monoethyl ether or other alkyl derivatives thereofas a primary vehicle or as a solvent system in preparation of Such (30) Foreign Application Priority Data pharmaceutical compositions. The pharmaceutical composi Apr. 2, 2013 (IN) ......................... 1287/MUMA2013 tions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formu Publication Classification lations containing such pharmaceutical actives and are Suit able for use as injectables for intravenous and intramuscular (51) Int. Cl. administration, as well as for use as a preformed solution/ A647/ (2006.01) liquid for filling in and preparation of capsules, tablets, nasal A6 IK 45/06 (2006.01) sprays, gargles, dermal applications, gels, topicals, liquid oral A6 IK9/00 (2006.01) dosage forms and other dosage forms.
    [Show full text]
  • Simulation of Physicochemical and Pharmacokinetic Properties of Vitamin D3 and Its Natural Derivatives
    pharmaceuticals Article Simulation of Physicochemical and Pharmacokinetic Properties of Vitamin D3 and Its Natural Derivatives Subrata Deb * , Anthony Allen Reeves and Suki Lafortune Department of Pharmaceutical Sciences, College of Pharmacy, Larkin University, Miami, FL 33169, USA; [email protected] (A.A.R.); [email protected] (S.L.) * Correspondence: [email protected] or [email protected]; Tel.: +1-224-310-7870 or +1-305-760-7479 Received: 9 June 2020; Accepted: 20 July 2020; Published: 23 July 2020 Abstract: Vitamin D3 is an endogenous fat-soluble secosteroid, either biosynthesized in human skin or absorbed from diet and health supplements. Multiple hydroxylation reactions in several tissues including liver and small intestine produce different forms of vitamin D3. Low serum vitamin D levels is a global problem which may origin from differential absorption following supplementation. The objective of the present study was to estimate the physicochemical properties, metabolism, transport and pharmacokinetic behavior of vitamin D3 derivatives following oral ingestion. GastroPlus software, which is an in silico mechanistically-constructed simulation tool, was used to simulate the physicochemical and pharmacokinetic behavior for twelve vitamin D3 derivatives. The Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) Predictor and PKPlus modules were employed to derive the relevant parameters from the structural features of the compounds. The majority of the vitamin D3 derivatives are lipophilic (log P values > 5) with poor water solubility which are reflected in the poor predicted bioavailability. The fraction absorbed values for the vitamin D3 derivatives were low except for calcitroic acid, 1,23S,25-trihydroxy-24-oxo-vitamin D3, and (23S,25R)-1,25-dihydroxyvitamin D3-26,23-lactone each being greater than 90% fraction absorbed.
    [Show full text]
  • Vitamin D to Prevent Exacerbations of COPD: Systematic Review and Meta- Analysis of Individual Participant Data from Randomised Controlled Trials
    Vitamin D to prevent exacerbations of COPD: systematic review and meta- analysis of individual participant data from randomised controlled trials APPENDIX Search Strategies A. PubMed Cochrane Highly Sensitive Search Strategy for identifying randomized controlled trials #1. randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab] #2. animals [mh] NOT humans [mh] #3. #1 NOT #2 Terms specific to vitamin D #4. Vitamin D OR vitamin D2 OR vitamin D3 OR cholecalciferol OR ergocalciferol OR alphacalcidol OR alfacalcidol OR calcitriol OR paricalcitol OR doxerocalciferol Terms specific to chronic obstructive pulmonary disease #5 COPD OR chronic obstructive pulmonary disease OR emphysema Combination of terms to identify randomized controlled trials of vitamin D conducted in patients with asthma #3 AND #4 AND #5 B. EMBASE Terms for identifying randomized controlled trials #1 ‘randomized controlled trial’/exp OR ‘single blind procedure’/exp OR ‘double blind procedure’/exp OR ’crossover procedure’/exp #2 random*:ab,ti OR placebo*:ab,ti OR crossover*:ab,ti OR ’cross over’:ab,ti OR allocat*:ab,ti OR ((singl* OR doubl*) NEXT/1 blind*):ab,ti OR trial:ti #3. #1 OR #2 1 Terms specific to vitamin D #4. vitamin AND d OR vitamin AND d2 OR vitamin AND d3 OR cholecalciferol OR ergocalciferol OR alphacalcidol OR alfacalcidol OR calcitriol OR paricalcitol OR doxerocalciferol Terms specific to chronic obstructive pulmonary disease #5. Chronic Obstructive Pulmonary Disease OR COPD OR COAD OR emphysema OR chronic bronchitis OR AECB OR AECOPD Combination of terms to identify randomized controlled trials of vitamin D conducted in patients with chronic obstructive pulmonary disease #3 AND #4 AND #5 C.
    [Show full text]
  • Vitamin D and Cancer
    WORLD HEALTH ORGANIZATION INTERNATIONAL AGENCY FOR RESEARCH ON CANCER Vitamin D and Cancer IARC 2008 WORLD HEALTH ORGANIZATION INTERNATIONAL AGENCY FOR RESEARCH ON CANCER IARC Working Group Reports Volume 5 Vitamin D and Cancer - i - Vitamin D and Cancer Published by the International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France © International Agency for Research on Cancer, 2008-11-24 Distributed by WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]) Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or of certain manufacturer’s products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. The authors alone are responsible for the views expressed in this publication. The International Agency for Research on Cancer welcomes requests for permission to reproduce or translate its publications, in part or in full.
    [Show full text]
  • Softgel Healthcare Private Limited - Product List
    Softgel Healthcare Private Limited - Product List # Generic Name Label Claim Acetaminophen Each soft gelatin capsule contains: 325mg,Dextromethorphan Acetaminophen USP 325mg 1 Hydrobromide15mg with Dextromethorphan Hydrobromide BP 15mg Pseudoephedrine HCL30mg Capsules Pseudoephedrine Hydrochloride BP 30mg Each soft gelatin capsule contains: 2 Acetaminophen Capsules 500 mg Acetaminophen USP 500 mg Each soft gelatin capsule contains: 3 Acetaminophen Capsules 650 mg Acetaminophen USP 650 mg Each soft gelatin capsule contains: Acetaminophen 500 mg with Caffeine 4 Acetaminophen USP 500mg 25 mg Capsules Caffeine USP 25mg Each soft gelatin capsule contains: Acetaminophen 325 mg , Caffeine 30 Acetaminophen USP 325mg 5 mg with Ibuprofen 200 mg Capsules Caffeine USP 30mg Ibuprofen USP 200mg Each soft gelatin capsule contains: Acetaminophen, Dextromethorphan Acetaminophen USP 325mg 6 Hydrobromide with Chlorpheniramine Dextromethorphan Hydrobromide USP 15mg Maleate Capsules Chlorpheniramine Maleate USP 4mg Each soft gelatin capsule contains: Acetaminophen, Dextromethorphan Acetaminophen USP 325mg 7 Hydrobromide with Doxylamine Dextromethorphan Hydrobromide USP 10mg Succinate Capsules Doxylamine Succinate USP 6.25mg Each soft gelatin capsule contains: Acetaminophen, Dextromethorphan Acetaminophen USP 325 mg 8 Hydrobromide with Doxylamine Dextromethorphan Hydrobromide USP 15 mg Succinate Capsules Doxylamine Succinate USP 6.25 mg Each soft gelatin capsule contains: Acetaminophen, dextromethorphan HBr Acetaminophen USP 325mg 9 with phenylephrine Hcl
    [Show full text]
  • Nutrition and Blood
    Greater Manchester Joint Formulary Chapter 9: Nutrition and Blood For cost information please go to the most recent cost comparison charts Contents 9.1. Anaemias and some other blood disorders 9.2 Fluids and electrolytes 9.3 Not listed 9.4. Oral nutrition 9.5 Minerals 9.6 Vitamins Key Red drug see GMMMG RAG list Click on the symbols to access this list Amber drug see GMMMG RAG list Click on the symbols to access this list Green drug see GMMMG RAG list Click on the symbols to access this list If a medicine is unlicensed this should be highlighted in the template as follows Drug name Not Recommended OTC Over the Counter In line with NHS England guidance, GM do not routinely support prescribing for conditions which are self-limiting or amenable to self-care. For further details see GM commissioning statement. Order of Drug Choice Where there is no preferred 1st line agent provided, the drug choice appears in alphabetical order. Return to contents Chapter 9 – page 1 of 16 V5.2 Greater Manchester Joint Formulary BNF chapter 9 Nutrition and Blood Section 9.1. Anaemias and some other blood disorders Subsection 9.1.1 Iron-deficiency anaemias Subsection 9.1.1.1 Oral iron First choice Ferrous fumarate 322 mg tabs (100 mg iron) Ferrous fumarate 305 mg caps (100 mg iron) Alternatives Ferrous fumarate 210 mg tabs (68 mg iron) Ferrous sulphate 200 mg tabs (65 mg iron) Ferrous fumarate 140 mg sugar free syrup (45 mg of iron/5 mL) Sodium feredetate 190 mg sugar free elixir (27.5 mg of iron/5 mL) Grey drugs Ferric maltol capsules Items which Criterion 2 (see RAG list) are listed as For treatment of iron deficiency anaemia in patients with Grey are intolerance to, or treatment failure with, two oral iron deemed not supplements.
    [Show full text]